MSD Mexico Warns Of Counterfeiting

6 April 1997

The Mexican subsidiary of Merck & Co, Merck, Sharp & Dohme, has takenout newspaper, radio and television announcements to warn the Mexican public that counterfeit versions of its injectable Decadron (dexamethasone) are on the market.

The public warning, which has been made in cooperation with the Ministry of Health, does not mention the number of suspected units of the drug which might be on the market. The media announcement told consumers that if they have injectable Decadron in their possession, not to use it, but to return it to the pharmacy immediately.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight